Details

Autor(en) / Beteiligte

• Schächinger, Volker
• Erbs, Sandra
• Elsässer, Albrecht
• Haberbosch, Werner
• Hambrecht, Rainer
• Hölschermann, Hans
• Yu, Jiangtao
• Corti, Roberto
• Mathey, Detlef G
• Hamm, Christian W
• Süselbeck, Tim
• Assmus, Birgit
• Tonn, Torsten
• Dimmeler, Stefanie
• Zeiher, Andreas M

Titel

Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction

Ist Teil von

• The New England journal of medicine, 2006-09, Vol.355 (12), p.1210-1221

Ort / Verlag

Boston, MA: Massachusetts Medical Society

Erscheinungsjahr

2006

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The infusion of bone marrow–derived progenitor cells into the infarct-related coronary artery after an acute myocardial infarction was associated with an absolute increase in the ejection fraction of 5.5%. Determining whether this modest improvement in ventricular function will translate into a long-term clinical benefit will require larger trials with longer follow-up. The infusion of bone marrow–derived progenitor cells into the infarct-related coronary artery after an acute myocardial infarction was associated with an absolute increase in the ejection fraction of 5.5%. Prompt reperfusion of the infarct-related coronary artery has considerably improved the clinical outcome in patients with acute myocardial infarction. 1 Although contemporary reperfusion strategies using stent implantation and aggressive inhibition of platelet aggregation have been shown to increase myocardial salvage, 2 improvements in global left ventricular function are rather modest, despite the use of optimal reperfusion therapy. 3 , 4 Heart failure that develops after infarction remains a major cause of morbidity and mortality. 5 , 6 Experimental studies suggested that intravascular or intramyocardial administration of progenitor cells derived from bone marrow (BMC) or blood may contribute to functional regeneration of infarcted myocardium and enhance neovascularization . . .